Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$0.11
$0.00
$0.90
N/A-1536.71,715 shsN/A
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
$6.48
$6.48
$2.11
$8.74
$28.12M0.6612,055 shsN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$0.72
-5.4%
$0.73
$0.60
$5.15
$3.47M1.46517,960 shs104,081 shs
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$4.52
-2.3%
$4.02
$3.03
$14.80
$4.13M1.25138,515 shs836 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
0.00%0.00%0.00%-99.99%-99.99%
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
0.00%0.00%0.00%0.00%0.00%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-5.49%+0.59%-1.39%-7.10%-83.92%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
-0.84%+6.57%+20.31%+17.86%-27.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
2.5628 of 5 stars
3.53.00.00.02.90.01.3
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.9008 of 5 stars
0.04.00.00.03.30.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
0.00
N/AN/AN/A
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
0.00
N/AN/AN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
3.00
Buy$12.001,534.88% Upside
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest FRLN, TTNP, PALI, and ELOX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/AN/AN/AN/A$12.07 per shareN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$250K14.08N/AN/A$18.29 per share0.04
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$180K22.93N/AN/A$8.82 per share0.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
-$36.06MN/A0.00N/AN/AN/AN/AN/AN/A
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
-$88.97M-$5.59N/AN/AN/AN/A-150.46%-97.01%N/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$12.30M-$6.80N/AN/AN/AN/A-148.51%-115.16%8/11/2025 (Estimated)
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
-$5.57M-$4.59N/AN/AN/A-118.01%-103.79%8/13/2025 (Estimated)

Latest FRLN, TTNP, PALI, and ELOX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A-$0.62N/A-$0.62N/AN/A
5/12/2025Q1 2025
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$0.84-$0.47+$0.37-$0.47N/AN/A
3/24/2025Q4 2024
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$2.39-$0.69+$1.70-$0.69N/AN/A
3/20/2025Q4 2024
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A-$0.85N/A-$0.85N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/AN/AN/AN/AN/A
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/AN/AN/AN/AN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
N/AN/AN/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/AN/AN/A
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/A
1.95
N/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
N/A
3.31
3.31
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A
9.71
9.71

Institutional Ownership

CompanyInstitutional Ownership
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
2.90%
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
46.26%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
11.79%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
31.49%

Insider Ownership

CompanyInsider Ownership
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
20.20%
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
1.90%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
3.28%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
303.14 million2.51 millionNot Optionable
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
1524.34 million4.26 millionNot Optionable
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
104.80 million2.68 millionNot Optionable
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
10914,000686,000Optionable

Recent News About These Companies

Titan Pharmaceuticals: Q4 Earnings Snapshot
Titan Pharmaceuticals receives Nasdaq notice of non-compliance
Titan Pharmaceuticals, Inc. (TTNP)
(TTNP) Technical Pivots with Risk Controls
When (TTNP) Moves Investors should Listen
Titan Pharmaceuticals Share Price (TTNP.US)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eloxx Pharmaceuticals stock logo

Eloxx Pharmaceuticals NASDAQ:ELOX

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Freeline Therapeutics stock logo

Freeline Therapeutics NASDAQ:FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Palisade Bio stock logo

Palisade Bio NASDAQ:PALI

$0.72 -0.04 (-5.42%)
As of 01:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Titan Pharmaceuticals stock logo

Titan Pharmaceuticals NASDAQ:TTNP

$4.51 -0.11 (-2.27%)
As of 01:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.